LBRX
LB Pharmaceuticals Inc
Price Chart
Latest Quote
$31.03
+0.55 (+1.80%)
Current Price
| Previous Close | $30.48 |
| Open | $30.49 |
| Day High | $31.99 |
| Day Low | $30.45 |
| Volume | 138,266 |
Stock Information
| Shares Outstanding | 28.68M |
| Total Debt | $3.47M |
| Cash Equivalents | $365.64M |
| Net Income | $-38.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $889.84M |
| EPS (TTM) | $-1.36 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $511.90M |
| Income | $-38.95M |
| Book/sh | $13.21 |
| Cash/sh | $12.75 |
| Employees | 35 |
Financial Ratios
| Quick Ratio | 33.53 |
| Current Ratio | 35.67 |
| Debt/Eq | 0.92 |
Returns & Margins
| ROE | -19.56% |
Ownership
| Insider Ownership | 0.27% |
| Institutional Ownership | 106.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.91 |
| P/B | 2.35 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $45.00 |
Technical Indicators
| SMA20 | $28.91 |
| SMA50 | $29.86 |
| RSI | 64.37 |
| ATR | 1.6484 |
| Shares Float | 18.10M |
| Short Float | 16.85% |
| Short Ratio | 25.86 |
| Rel Volume | 0.55 |
Performance History
| Week | +3.26% |
| Month | +9.53% |
| Quarter | +28.17% |
| 6 Months | +37.67% |
| YTD | +51.81% |
| 10 Years | +79.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $31.03 | 138,266 |
| 2026-06-24 | $30.48 | 295,000 |
| 2026-06-23 | $30.60 | 824,500 |
| 2026-06-22 | $29.87 | 345,000 |
| 2026-06-18 | $30.00 | 513,100 |
| 2026-06-17 | $30.05 | 334,400 |
| 2026-06-16 | $27.66 | 160,300 |
| 2026-06-15 | $28.50 | 202,000 |
| 2026-06-12 | $28.42 | 158,400 |
| 2026-06-11 | $28.54 | 120,000 |
| 2026-06-10 | $28.39 | 193,600 |
| 2026-06-09 | $29.27 | 362,800 |
| 2026-06-08 | $29.40 | 99,800 |
| 2026-06-05 | $28.53 | 156,800 |
| 2026-06-04 | $28.90 | 167,900 |
| 2026-06-03 | $27.95 | 198,400 |
| 2026-06-02 | $27.02 | 147,300 |
| 2026-06-01 | $28.03 | 126,900 |
| 2026-05-29 | $27.97 | 358,100 |
| 2026-05-28 | $27.53 | 109,000 |
| 2026-05-27 | $27.80 | 200,400 |
| 2026-05-26 | $28.33 | 129,000 |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
đ° Latest News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Motley Fool âĸ 2026-06-08T11:16:03Z
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
Zacks âĸ 2026-05-26T16:00:04Z
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-05-14T11:02:02Z
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
MarketBeat âĸ 2026-04-17T02:03:43Z
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-26T20:21:11ZLB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
MarketBeat âĸ 2026-03-20T19:08:16Z
LB Pharmaceuticals initiates Phase 2 trial of LB-102
TipRanks âĸ 2026-01-27T13:06:11Z
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T13:12:44ZCrunching the numbers on this week's IPO performances
Yahoo Finance Video âĸ 2025-09-12T20:27:22ZLB Pharmaceuticals raises $285 million in US IPO
Reuters âĸ 2025-09-11T01:23:49Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $30,404,000 | $64,830,000 | $11,376,000 | $2,809,000 |
| Other Income Expense | $1,280,000 | $8,000 | $9,116,000 | $-9,460,000 |
| Net Non Operating Interest Income Expense | $3,920,000 | $1,721,000 | $-4,014,000 | $-2,078,000 |
| Operating Expense | $30,404,000 | $64,830,000 | $11,376,000 | $2,809,000 |
| General And Administrative Expense | $13,660,000 | $13,659,000 | $3,531,000 | $1,463,000 |
| Interest Expense | - | $0 | $4,825,000 | $2,151,000 |
| Interest Expense Non Operating | - | $0 | $4,825,000 | $2,151,000 |
| Other Non Operating Income Expenses | - | - | $-34,000 | $-5,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Net Interest Income | $3,920,000 | $1,721,000 | $-4,014,000 | $-2,078,000 |
| Interest Income | $3,920,000 | $1,721,000 | $811,000 | $73,000 |
| Normalized Income | $-26,485,000 | $-63,110,000 | $-15,425,000 | $-6,878,550 |
| Net Income From Continuing And Discontinued Operation | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Total Operating Income As Reported | $-30,404,000 | $-64,830,000 | $-11,376,000 | $-2,809,000 |
| Net Income Common Stockholders | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Net Income | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Net Income Including Noncontrolling Interests | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Net Income Continuous Operations | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Pretax Income | $-25,204,000 | $-63,101,000 | $-6,274,000 | $-14,347,000 |
| Interest Income Non Operating | $3,920,000 | $1,721,000 | $811,000 | $73,000 |
| Operating Income | $-30,404,000 | $-64,830,000 | $-11,376,000 | $-2,809,000 |
| Special Income Charges | - | $0 | $-7,435,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-3.13 | $-17.82 | $-1.77 | $-4.05 |
| Basic EPS | $-3.13 | $-17.82 | $-1.77 | $-4.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-1,985,550 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-31,363,000 | $-64,747,000 | $-10,595,000 | $-2,739,000 |
| Total Unusual Items | $1,280,000 | $8,000 | $9,150,000 | $-9,455,000 |
| Total Unusual Items Excluding Goodwill | $1,280,000 | $8,000 | $9,150,000 | $-9,455,000 |
| Reconciled Depreciation | $321,000 | $91,000 | $4,000 | $2,000 |
| EBITDA (Bullshit earnings) | $-30,083,000 | $-64,739,000 | $-1,445,000 | $-12,194,000 |
| EBIT | $-30,404,000 | $-64,830,000 | $-1,449,000 | $-12,196,000 |
| Diluted Average Shares | $8,045,145 | $22,442,989 | $22,442,989 | $22,442,989 |
| Basic Average Shares | $8,045,145 | $3,540,753 | $3,540,753 | $3,540,753 |
| Diluted NI Availto Com Stockholders | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Tax Provision | $1,000 | $1,000 | $1,000 | $1,000 |
| Gain On Sale Of Security | $1,280,000 | $8,000 | $16,585,000 | $-9,455,000 |
| Research And Development | $16,744,000 | $51,171,000 | $7,845,000 | $1,346,000 |
| Selling General And Administration | $13,660,000 | $13,659,000 | $3,531,000 | $1,463,000 |
| Other Gand A | $13,660,000 | $13,659,000 | $3,531,000 | $1,463,000 |
| Other Special Charges | - | - | $7,435,000 | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $301,310,000 | $-94,554,000 | $-34,473,000 | $-28,812,000 |
| Total Assets | $312,934,000 | $33,534,000 | $45,657,000 | $21,492,000 |
| Total Non Current Assets | $4,502,000 | $4,655,000 | $23,000 | $3,000 |
| Other Non Current Assets | $770,000 | $498,000 | - | - |
| Current Assets | $308,432,000 | $28,879,000 | $45,634,000 | $21,489,000 |
| Other Current Assets | $478,000 | $132,000 | $21,000 | $9,000 |
| Prepaid Assets | $12,741,000 | $748,000 | $2,317,000 | $76,000 |
| Cash Cash Equivalents And Short Term Investments | $295,213,000 | $27,999,000 | $43,291,000 | $21,404,000 |
| Cash And Cash Equivalents | $250,173,000 | $22,978,000 | $14,979,000 | $21,404,000 |
| Current Deferred Assets | - | $0 | $5,000 | - |
| Debt | ||||
| Total Debt | $3,569,000 | $3,703,000 | $0 | $24,148,000 |
| Long Term Debt And Capital Lease Obligation | $2,839,000 | $3,216,000 | $0 | $24,148,000 |
| Current Debt And Capital Lease Obligation | $730,000 | $487,000 | - | - |
| Net Debt | - | - | - | $2,744,000 |
| Long Term Debt | - | - | - | $24,148,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,624,000 | $128,088,000 | $80,130,000 | $50,304,000 |
| Total Non Current Liabilities Net Minority Interest | $4,182,000 | $119,979,000 | $77,524,000 | $49,835,000 |
| Derivative Product Liabilities | $1,343,000 | $2,504,000 | $1,557,000 | $17,454,000 |
| Current Liabilities | $7,442,000 | $8,109,000 | $2,606,000 | $469,000 |
| Payables And Accrued Expenses | $4,517,000 | $5,381,000 | $1,808,000 | $248,000 |
| Payables | $2,127,000 | $2,320,000 | $1,389,000 | $156,000 |
| Accounts Payable | $2,127,000 | $2,320,000 | $1,389,000 | $156,000 |
| Equity | ||||
| Common Stock Equity | $301,310,000 | $-94,554,000 | $-34,473,000 | $-28,812,000 |
| Total Equity Gross Minority Interest | $301,310,000 | $-94,554,000 | $-34,473,000 | $-28,812,000 |
| Stockholders Equity | $301,310,000 | $-94,554,000 | $-34,473,000 | $-28,812,000 |
| Gains Losses Not Affecting Retained Earnings | $168,000 | $111,000 | $274,000 | $0 |
| Other Equity Adjustments | $168,000 | $111,000 | $274,000 | - |
| Retained Earnings | $-129,528,000 | $-104,323,000 | $-41,221,000 | $-34,946,000 |
| Preferred Securities Outside Stock Equity | $0 | $114,259,000 | $75,967,000 | $7,194,000 |
| Other | ||||
| Ordinary Shares Number | $25,299,372 | $22,442,989 | $22,442,989 | $22,442,989 |
| Share Issued | $25,299,372 | $22,442,989 | $22,442,989 | $22,442,989 |
| Tangible Book Value | $301,310,000 | $-94,554,000 | $-34,473,000 | $-28,812,000 |
| Invested Capital | $301,310,000 | $-94,554,000 | $-34,473,000 | $-4,664,000 |
| Working Capital | $300,990,000 | $20,770,000 | $43,028,000 | $21,020,000 |
| Capital Lease Obligations | $3,569,000 | $3,703,000 | $0 | - |
| Total Capitalization | $301,310,000 | $-94,554,000 | $-34,473,000 | $-4,664,000 |
| Additional Paid In Capital | $430,667,000 | $9,657,000 | $6,473,000 | $6,133,000 |
| Capital Stock | $3,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $3,000 | $1,000 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $2,839,000 | $3,216,000 | $0 | - |
| Current Capital Lease Obligation | $730,000 | $487,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $2,195,000 | $2,241,000 | $798,000 | $221,000 |
| Current Accrued Expenses | $2,390,000 | $3,061,000 | $419,000 | $92,000 |
| Net PPE | $3,732,000 | $4,157,000 | $23,000 | $3,000 |
| Accumulated Depreciation | $-420,000 | $-101,000 | $-11,000 | $-7,000 |
| Gross PPE | $4,152,000 | $4,258,000 | $34,000 | $10,000 |
| Leases | $1,491,000 | $1,491,000 | $0 | - |
| Other Properties | $2,151,000 | $2,298,000 | - | - |
| Machinery Furniture Equipment | $510,000 | $469,000 | $34,000 | $10,000 |
| Properties | $0 | $0 | $0 | - |
| Other Short Term Investments | $45,040,000 | $5,021,000 | $28,312,000 | $0 |
| Non Current Accrued Expenses | - | - | $0 | $1,039,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-35,260,000 | $-53,821,000 | $-12,119,000 | $-2,728,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-35,208,000 | $-53,052,000 | $-12,094,000 | $-2,728,000 |
| Cash Flow From Continuing Operating Activities | $-35,208,000 | $-53,052,000 | $-12,094,000 | $-2,728,000 |
| Operating Gains Losses | $-1,272,000 | $-8,000 | $-9,150,000 | $9,455,000 |
| Investing Activities | ||||
| Capital Expenditure | $-52,000 | $-769,000 | $-25,000 | - |
| Investing Cash Flow | $-39,887,000 | $23,234,000 | $-28,010,000 | $123,000 |
| Cash Flow From Continuing Investing Activities | $-39,887,000 | $23,234,000 | $-28,010,000 | $123,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $327,750,000 | $40,000,000 | $35,000,000 | $903,000 |
| Financing Cash Flow | $302,562,000 | $38,315,000 | $33,679,000 | $22,962,000 |
| Cash Flow From Continuing Financing Activities | $302,562,000 | $38,315,000 | $33,679,000 | $22,962,000 |
| Net Other Financing Charges | $-25,435,000 | $-1,708,000 | $-2,047,000 | $-2,946,000 |
| Net Preferred Stock Issuance | $0 | $40,000,000 | $35,000,000 | $903,000 |
| Preferred Stock Issuance | $0 | $40,000,000 | $35,000,000 | $903,000 |
| Net Common Stock Issuance | $327,750,000 | $0 | - | - |
| Common Stock Issuance | $327,750,000 | $0 | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $1,981,000 | $0 |
| Income Tax Paid Supplemental Data | $1,000 | $1,000 | $1,000 | $1,000 |
| End Cash Position | $250,943,000 | $23,476,000 | $14,979,000 | $21,404,000 |
| Beginning Cash Position | $23,476,000 | $14,979,000 | $21,404,000 | $1,047,000 |
| Changes In Cash | $227,467,000 | $8,497,000 | $-6,425,000 | $20,357,000 |
| Proceeds From Stock Option Exercised | $247,000 | $23,000 | $1,000 | $0 |
| Net Investment Purchase And Sale | $-39,835,000 | $24,003,000 | $-27,985,000 | $123,000 |
| Sale Of Investment | $5,001,000 | $53,749,000 | $6,000,000 | $123,000 |
| Purchase Of Investment | $-44,836,000 | $-29,746,000 | $-33,985,000 | $0 |
| Net PPE Purchase And Sale | $-52,000 | $-769,000 | $-25,000 | $0 |
| Purchase Of PPE | $-52,000 | $-769,000 | $-25,000 | $0 |
| Change In Working Capital | $-13,651,000 | $3,313,000 | $-1,313,000 | $86,000 |
| Change In Other Current Liabilities | $-134,000 | $-60,000 | $0 | - |
| Change In Payables And Accrued Expense | $-910,000 | $5,016,000 | $1,098,000 | $131,000 |
| Change In Prepaid Assets | $-12,339,000 | $-1,757,000 | $-2,257,000 | $-45,000 |
| Change In Receivables | $-268,000 | $114,000 | $-154,000 | - |
| Other Non Cash Items | $147,000 | $308,000 | $3,917,000 | $1,646,000 |
| Stock Based Compensation | $4,191,000 | $3,161,000 | $295,000 | $431,000 |
| Asset Impairment Charge | $0 | $3,219,000 | $0 | - |
| Amortization Of Securities | $261,000 | $-34,000 | $428,000 | - |
| Depreciation Amortization Depletion | $321,000 | $91,000 | $4,000 | $2,000 |
| Depreciation And Amortization | $321,000 | $91,000 | $4,000 | $2,000 |
| Depreciation | $321,000 | $91,000 | $4,000 | $2,000 |
| Gain Loss On Investment Securities | $-1,280,000 | $-8,000 | $-16,585,000 | $9,455,000 |
| Gain Loss On Sale Of PPE | $8,000 | $0 | - | - |
| Net Income From Continuing Operations | $-25,205,000 | $-63,102,000 | $-6,275,000 | $-14,348,000 |
| Issuance Of Debt | - | $0 | $725,000 | $25,005,000 |
| Net Issuance Payments Of Debt | - | $0 | $725,000 | $25,005,000 |
| Net Long Term Debt Issuance | - | $0 | $725,000 | $25,005,000 |
| Long Term Debt Issuance | - | $0 | $725,000 | $25,005,000 |
Fetched: 2026-06-23